Adriamycin was given in a dose of 25 to 45 mg/m2 of bodrface area to 9 patients with multiple myeloma who had failed to respond to intermittent therapy with melphalan and prednisone. Three patients had evidence of clinical remission and in 2 of them there was a 60% decrease in total body myeloma cell number. However, remissions were of short duration (3 mth in 2 patients and over 10 months in another patient) and bone marrow suppression was moderately severe. Adriamycin may prove more useful in myeloma therapy when combined with melphalan or cyclophosphamide during the initial attempt at remission induction.
|Original language||English (US)|
|Number of pages||6|
|State||Published - Dec 1 1975|
ASJC Scopus subject areas